Previous 10 | Next 10 |
80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus ei...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
Mr. Jordan to build commercial infrastructure in advance of potential Emergency Use Authorization of lenzilumab Humanigen, Inc. , (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...
Seres Therapeutics stock jumps on positive topline data Seres Therapeutics Inc. ( MCRB ) stock recorded swift boost as the company announced positive data from its Phase 3 ECOSPOR III study. The company reported that the drug candidate was able to bring about statistically significant ch...
Relief Therapeutics Holdings AG ( RLFTF ) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a propr...
Brazil's Anvisa regulatory agency has signed off on a Phase 3 clinical trial evaluating Humanigen's ( OTCQB:HGEN +2.4% ) lead drug lenzilumab in hospitalized severely ill and critically ill COVID-19 patients at high risk of disease progression. More news on: Humanigen, Inc., Healthcare...
Study approval by Brazil’s ministry of health follows IND approval granted by the FDA in the US Brazil represents an important component of Humanigen’s global development program for lenzilumab Humanigen, Inc. , (HGEN) (“Humanigen”), a clinical ...
Management presentation today, August 10 at 2:00 pm EDT Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and bu...
Role will build on existing Humanigen Asia-Pacific activities and focus on regional clinical development, commercialization, business and corporate development BURLINGAME, CA / ACCESSWIRE / August 6, 2020 / Humanigen, Inc . (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceu...
Management presentation Monday, August 10 at 2:00 pm EDT Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and b...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...